Friday, November 16, 2012

Exjade receives EU CHMP nod for approval to treat patients with non transfusion dependent thalassemia syndrome

If approved Exjade would be the first oral treatment in Europe for patients with non-transfusion-dependent thalassemia (NTDT) syndromes. Clinical data show Exjade significantly decreases iron burden in NTDT patients compared to placebo, with similar overall adverse event rate.
NTDT patients accumulate excess iron, increasing their risk of complications, including liver fibrosis, cirrhosis, blood clots and bone and vascular disease.

Exjade has been approved to treat chronic iron overload in patients with NTDT in Canada and several other countries; while further regulatory submissions are ongoing


Enter your email address:


Delivered by FeedBurner